Zhang et al. prospectively investigated the role of several miRNAs in 37 luminal B BC patients undergoing NAC with taxane- and/or anthracycline-based regimens, plus trastuzumab for HER2-positive cases. The gene discussed is ERBB2; the disease is breast cancer.